Drug Database · Clinicians

Cefepime

Brands (78) Axera, Zepime, Cepiram…Show all

Antibacterials (cephalosporins); Antibacterial (fourth-generation cephalosporin); and others PH FDA category

CrCl ≤60: reduce; dose after HDRx · Prescription drug103 PH productsPNF-listed Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID de477f37-40f6-4295-ae72-a2ee36a8922e, version date August 3, 2026 (cefepime · Sagent Pharmaceuticals). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Cefepime for Injection is a cephalosporin antibacterial indicated for the treatment of the following infections caused by susceptible strains of the designated microorganisms: Pneumonia.
  • Empiric therapy for febrile neutropenic patients.
  • Uncomplicated and complicated urinary tract infections (including pyelonephritis).
  • Uncomplicated skin and skin structure infections.
  • Complicated intra-abdominal infections (used in combination with metronidazole) in adults.
  • To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime for Injection and other antibacterial drugs, Cefepime for Injection should be used only to treat or prevent infections that…
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE Cefepime for Injection is a cephalosporin antibacterial indicated for the treatment of the following infections caused by susceptible strains of the designated microorganisms: Pneumonia. (1.1) Empiric therapy for febrile neutropenic patients. (1.2) Uncomplicated and complicated urinary tract infections (including pyelonephritis).

(1.3) Uncomplicated skin and skin structure infections. (1.4) Complicated intra-abdominal infections (used in combination with metronidazole) in adults. (1.5) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime for Injection and other antibacterial drugs, Cefepime for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

(1.6) 1.1 Pneumonia Cefepime for Injection is indicated in the treatment of pneumonia (moderate to severe) caused by susceptible strains of Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae, or Enterobacter species. 1.2 Empiric Therapy for Febrile Neutropenic Patients Cefepime for Injection as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate.

Insufficient data exist to support the efficacy of cefepime monotherapy in such patients [see Clinical Studies (14.1)]. 1.3 Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) Cefepime for Injection is indicated in the treatment of uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by susceptible isolates of Escherichia coli or Klebsiella pneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these bacteria. 1.4 Uncomplicated Skin and Skin Structure Infections Cefepime for Injection is indicated in the treatment of uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes. 1.5 Complicated Intra-abdominal Infections (used in combination with metronidazole) Cefepime for Injection is indicated in the treatment of complicated intra-abdominal infections (used in combination with metronidazole) in adults caused by susceptible isolates of Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter species, or Bacteroides fragilis [see Clinical Studies (14.2)]. 1.6 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime for Injection and other antibacterial drugs, Cefepime for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.

In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Contraindications

  • Immediate hypersensitivity to cefepime, cephalosporins, penicillins or other beta-lactams
renalcarematters.com, reviewed
Contraindications (US label) US FDA label

4 CONTRAINDICATIONS Cefepime for injection is contraindicated in patients who have shown immediate hypersensitivity reactions to cefepime or the cephalosporin class of antibacterial drugs, penicillins or other beta-lactam antibacterial drugs. Patients with known immediate hypersensitivity reactions to cefepime or other cephalosporins, penicillins or other beta-lactam antibacterial drugs. (4)

Dosing: Adult

  • Moderate to severe pneumonia: 1 to 2 g IV every 8 to 12 hours (P. aeruginosa: 2 g every 8 hours)
  • Empiric therapy, febrile neutropenia: 2 g IV every 8 hours
  • Mild to moderate urinary tract infection: 0.5 to 1 g IV or IM every 12 hours
  • Severe urinary tract infection: 2 g IV every 12 hours
  • Skin and skin structure infection: 2 g IV every 12 hours
  • Complicated intra-abdominal infection (with metronidazole): 2 g IV every 8 to 12 hours
  • CrCl 60 mL/min or less: See kidney table: same first dose, then reduced maintenance by CrCl
renalcarematters.com, reviewed
Dosage and administration (US label) US FDA label
  • § For Pseudomonas aeruginosa, use 2 g IV every 8 hours. (2.1)
  • * Or until resolution of neutropenia. (2.1)
  • ** Intramuscular route of administration is indicated only for mild to moderate, uncomplicated or complicated UTIs due to E. coli. (2.1)
  • Recommended Dosage in Adults with Creatinine Clearance (CrCL) Greater Than 60 mL/min (2.1)
  • Site and Type of Infection Dose Frequency Duration (days) Moderate to Severe Pneumonia § 1 to 2 g IV Every 8 to 12 hours 10 Empiric Therapy for Febrile Neutropenic Patients 2 g IV Every 8 hours 7* Mild to Moderate Uncomplicated or Complicated Urinary Tract Infections 0.5 to 1 g IV/IM** Every 12 hours 7 to 10 Severe Uncomplicated or Complicated Urinary Tract Infections 2 g IV Every 12 hours 10 Moderate to Severe Uncomplicated Skin and Skin Structure Infections 2 g IV Every 12 hours 10 Complicated Intra-abdominal Infections § (used in combination with metronidazole) 2 g IV Every 12 hours 7 to 10 Pediatric Patients (2 months to 16 years) Recommended dosage in pediatric with CrCL greater than 60 mL/min. (2.2)
  • The usual recommended dosage in pediatric patients is 50 mg per kg per dose administered every 12 hours (every 8 hours for febrile neutropenia). (2.2)
  • Patients with Renal Impairment: Adjust dose in patients with CrCL less than or equal to 60 mL/min. (2.3)
2.1 Dosage for Adults

2.1 Dosage for Adults The recommended adult dosages and routes of administration are outlined in Table 1 below for patients with creatinine clearance greater than 60 mL/min. Administer cefepime for injection intravenously over approximately 30 minutes. Table 1: Recommended Dosage Schedule for Cefepime for Injection in Adult Patients with Creatinine Clearance (CrCL) Greater Than 60 mL/min * or until resolution of neutropenia.

In patients whose fever resolves but who remain neutropenic for more than 7 days, the need for continued antimicrobial therapy should be re-evaluated frequently. ** Intramuscular route of administration is indicated only for mild to moderate, uncomplicated or complicated UTIs due to E. coli. § For P. aeruginosa, use 2 g IV every 8 hours. Site and Type of Infection Dose Frequency Duration (days) Adults Intravenous (IV)/ Intramuscular (IM) Moderate to Severe Pneumonia § 1 to 2 g IV Every 8 to 12 hours 10 Empiric therapy for febrile neutropenic patients 2 g IV Every 8 hours 7* Mild to Moderate Uncomplicated or Complicated Urinary Tract Infections, including pyelonephritis 0.5 to 1 g IV/IM** Every 12 hours 7 to 10 Severe Uncomplicated or Complicated Urinary Tract Infections, including pyelonephritis 2 g IV Every 12 hours 10 Moderate to Severe Uncomplicated Skin and Skin Structure Infections 2 g IV Every 12 hours 10 Complicated Intra-abdominal Infections § (used in combination with metronidazole) 2 g IV Every 8 to 12 hours 7 to 10

2.2 Pediatric Patients (2 months up to 16 years)

2.2 Pediatric Patients (2 months up to 16 years) The maximum dose for pediatric patients should not exceed the recommended adult dose. The usual recommended dosage in pediatric patients up to 40 kg in weight for durations as given above for adults is: 50 mg per kg per dose, administered every 12 hours for uncomplicated and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin structure infections, and pneumonia (see below).

For moderate to severe pneumonia due to P. aeruginosa give 50 mg per kg per dose, every 8 hours. 50 mg per kg per dose, every 8 hours for febrile neutropenic patients.

2.3 Dosage Adjustments in Patients with Renal Impairment Adult

2.3 Dosage Adjustments in Patients with Renal Impairment Adult Patients Adjust the dose of cefepime for injection in patients with creatinine clearance less than or equal to 60 mL/min to compensate for the slower rate of renal elimination. In these patients, the recommended initial dose of cefepime for injection should be the same as in patients with CrCL greater than 60 mL/min except in patients undergoing hemodialysis.

The recommended doses of cefepime for injection in patients with renal impairment are presented in Table 2. When only serum creatinine is available, the following formula (Cockcroft and Gault equation) 1 may be used to estimate creatinine clearance. The serum creatinine should represent a steady state of renal function: Females: 0.85 x above value Table 2: Recommended Dosing Schedule for Cefepime for Injection in Adult Patients with Creatinine Clearance Less Than or Equal to 60 mL/min *On hemodialysis days, cefepime should be administered following hemodialysis.

Whenever possible, cefepime should be administered at the same time each day. Creatinine Clearance (mL/min) Recommended Maintenance Schedule Greater than 60 500 mg every 12 hours 1 g every 12 hours 2 g every 12 hours 2 g every 8 hours 30 to 60 500 mg every 24 hours 1 g every 24 hours 2 g every 24 hours 2 g every 12 hours 11 to 29 500 mg every 24 hours 500 mg every 24 hours 1 g every 24 hours 2 g every 24 hours Less than 11 250 mg every 24 hours 250 mg every 24 hours 500 mg every 24 hours 1 g every 24 hours Continuous Ambulatory Peritoneal Dialysis (CAPD) 500 mg every 48 hours 1 g every 48 hours 2 g every 48 hours 2 g every 48 hours Hemodialysis* 1 g on day 1, then 500 mg every 24 hours thereafter 1 g every 24 hours In patients undergoing Continuous Ambulatory Peritoneal Dialysis (CAPD), cefepime for injection may be administered at the recommended doses at a dosage interval of every 48 hours (see Table 2).

In patients undergoing hemodialysis, approximately 68% of the total amount of cefepime present in the body at the start of dialysis will be removed during a 3-hour dialysis period. The dosage of cefepime for injection for hemodialysis patients is 1 g on Day 1 followed by 500 mg every 24 hours for the treatment of all infections except febrile neutropenia, which is 1 g every 24 hours.

Cefepime for injection should be administered at the same time each day and following the completion of hemodialysis on hemodialysis days (see Table 2). Equation Pediatric Patients Data in pediatric patients with impaired renal function are not available; however, since cefepime pharmacokinetics are similar in adults and pediatric patients [see Clinical Pharmacology (12.3)], changes in the dosing regimen proportional to those in adults (see Tables 1 and 2) are recommended for pediatric patients.

2.4 Preparation of Cefepime for Injection for Intravenous Infusion Vials

2.4 Preparation of Cefepime for Injection for Intravenous Infusion Vials Constitute the 1 gram or 2 grams vial, of cefepime for injection with the one of the following diluents: Sterile Water for Injection 0.9% Sodium Chloride Injection 5% Dextrose Injection 0.5% or 1% Lidocaine Hydrochloride Injection Sterile Bacteriostatic Water for Injection with Parabens or Benzyl Alcohol Dilute the reconstituted solution with one of the following compatible infusion solutions prior to intravenous infusion (Refer to Table 3 below for the amount of diluent to be added to each vial and the amount of the reconstituted solution to be withdrawn): 0.9% Sodium Chloride Injection 5% and 10% Dextrose Injection M/6 Sodium Lactate Injection 5% Dextrose and 0.9% sodium Chloride Injection Lactated Ringers and 5% Dextrose Injection Normosol ® -R and Normosol ® -M in 5% Dextrose Injection Parenteral drugs should be inspected visually for particulate matter before administration. If particulate matter is evident in reconstituted fluids, the drug solution should be discarded.

Administer the resulting intravenous infusion over approximately 30 minutes. Intermittent intravenous infusion with a Y-type administration set can be accomplished with compatible solutions. However, during infusion of a solution containing cefepime, it is desirable to discontinue the other solution.

2.5 Preparation of Cefepime for Injection for Intramuscular Administration

2.5 Preparation of Cefepime for Injection for Intramuscular Administration Constitute cefepime for injection vials 1 gram and 2 grams with one of the following diluents: Sterile Water for Injection, 0.9% Sodium Chloride, 5% Dextrose Injection, 0.5% or 1% Lidocaine Hydrochloride, or Sterile Bacteriostatic Water for Injection with Parabens or Benzyl Alcohol. Refer to Table 3 below for the amount of diluent to be added to each vial and the amount of reconstituted volume to be withdrawn.

Parenteral drugs should be inspected visually for particulate matter before administration. If particulate matter is evident in reconstituted fluids, the drug solution should be discarded. Table 3: Preparation of Reconstituted Solutions of Cefepime for Injection Single-Dose Vials for Intravenous (IV)/ Intramuscular (IM) Administration Amount of Diluent to be added (mL) Approximate Cefepime Concentration (mg/mL) Amount of Reconstituted Volume to be Withdrawn (mL) Cefepime vial content 1 g (IV) 10 100 10.5 1 g (IM) 2.4 280 3.6 2 g (IV) 10 160 12.5

2.6 Compatibility and Stability Intravenous

2.6 Compatibility and Stability Intravenous Cefepime for Injection Intravenous Infusion Compatibility Cefepime for injection vials are compatible at concentrations between 1 mg per mL and 40 mg per mL with the following intravenous infusion fluids: 0.9% Sodium Chloride Injection, 5% and 10% Dextrose Injection, M/6 Sodium Lactate Injection, 5% Dextrose and 0.9% Sodium Chloride Injection, Lactated Ringers and 5% Dextrose Injection, Normosol ® -R, and Normosol ® -M in 5% Dextrose Injection. These solutions may be stored up to 24 hours at controlled room temperature 20°C to 25°C (68°F to 77°F) or 7 days in a refrigerator 2°C to 8°C (36°F to 46°F).

Admixture Compatibility Cefepime for injection admixture compatibility information is summarized in Table 4. Table 4: Cefepime Admixture Stability NS = 0.9% Sodium Chloride Injection. D5W = 5% Dextrose Injection. na = not applicable. RT/L = Ambient room temperature and light. Cefepime for injection Concentration Admixture and Concentration Intravenous (IV) Infusion Solutions RT/L (20° to 25°C) Stability Time for Refrigeration (2° to 8°C) 40 mg/mL Amikacin 6 mg/mL NS or D5W 24 hours 7 days 40 mg/mL Ampicillin 1 mg/mL D5W 8 hours 8 hours 40 mg/mL Ampicillin 10 mg/mL D5W 2 hours 8 hours 40 mg/mL Ampicillin 1 mg/mL NS 24 hours 48 hours 40 mg/mL Ampicillin 10 mg/mL NS 8 hours 48 hours 4 mg/mL Ampicillin 40 mg/mL NS 8 hours 8 hours 4 to 40 mg/mL Clindamycin Phosphate 0.25 to 6 mg/mL NS or D5W 24 hours 7 days 4 mg/mL Heparin 10 to 50 units/mL NS or D5W 24 hours 7 days 4 mg/mL Potassium Chloride 10 to 40 mEq/L NS or D5W 24 hours 7 days 4 mg/mL Theophylline 0.8 mg/mL D5W 24 hours 7 days 1 to 4 mg/mL na Aminosyn™ II 4.25% with electrolytes and calcium 8 hours 3 days 0.125 to 0.25 mg/mL na Inpersol™ with 4.25% dextrose 24 hours 7 days Cefepime for Injection Admixture Incompatibility Do not add solutions of cefepime for injection to solutions of ampicillin at a concentration greater than 40 mg per mL, or to metronidazole, vancomycin, gentamicin, tobramycin, netilmicin sulfate, or aminophylline because of potential interaction.

However, if concurrent therapy with cefepime for injection is indicated, each of these antibacterial drugs can be administered separately. Intramuscular Cefepime for Injection Cefepime for injection constituted as directed is stable for 24 hours at controlled room temperature 20ºC to 25ºC (68ºF to 77ºF) or for 7 days in a refrigerator 2ºC to 8ºC (36ºF to 46ºF) with the following diluents: Sterile Water for Injection, 0.9% Sodium Chloride Injection, 5% Dextrose Injection, Sterile Bacteriostatic Water for Injection with Parabens or Benzyl Alcohol, or 0.5% or 1% Lidocaine Hydrochloride.

Intramuscular and Intravenous Cefepime for Injection As with other cephalosporins, the color of cefepime for injection powder, as well as its solutions tend to darken depending on storage conditions; however, when stored as recommended, the product potency is not adversely affected.

Dosing: Altered kidney function

Cefepime is cleared mainly by the kidneys, and its clearance falls in proportion to creatinine clearance (CrCl). The US label keeps the first dose unchanged and reduces maintenance doses when CrCl is 60 mL/min or less, with set regimens for hemodialysis and CAPD. Unadjusted doses in kidney impairment cause neurotoxicity (encephalopathy, myoclonus, seizures, nonconvulsive status epilepticus).

Kidney function measure: Label uses CrCl (mL/min; Cockcroft–Gault); adjust at 60 or less.

Show full dosing details
CrCl ≥60 mL/min
CrCl >60: usual dose (label: 500 mg to 2 g every 8 to 12 hours by indication). CrCl of exactly 60: use the 30–60 row.
CrCl 30–59 mL/min
CrCl 30–60, by usual regimen: 500 mg q12h → 500 mg q24h; 1 g q12h → 1 g q24h; 2 g q12h → 2 g q24h; 2 g q8h → 2 g q12h. First dose as for normal function (label Table 2).
CrCl 15–29 mL/min
CrCl 11–29, by usual regimen: 500 mg q12h → 500 mg q24h; 1 g q12h → 500 mg q24h; 2 g q12h → 1 g q24h; 2 g q8h → 2 g q24h (label Table 2).
CrCl <15 mL/min (not on dialysis)
CrCl 11–14: as the 11–29 row. CrCl below 11, by usual regimen: 250 mg, 250 mg, 500 mg or 1 g every 24 hours respectively (label Table 2).
Hemodialysis (intermittent)
1 g on day 1, then 500 mg every 24 hours; for the 2 g every 8 hours regimen (febrile neutropenia) 1 g every 24 hours; give at the same time each day and after hemodialysis on dialysis days (label). A 3-hour session removes about 68% of the drug in the body. Literature option (not label): thrice-weekly after each session, 2 g, 2 g and 2 g (1/1/1.5 g and 1.5/1.5/2 g reported in limited data) (Tsai 2025). Troughs of 22 mg/L or more have been associated with neurotoxicity; stop if encephalopathy or myoclonus appears. These regimens are not weight-adjusted and come mostly from small pharmacokinetic studies; confirm the actual last and next session before each dose. See the site guide Antibiotic Stewardship in Hemodialysis (/guides/antibiotic-stewardship-dialysis.html).
Peritoneal dialysis
CAPD: the usual dose every 48 hours (500 mg, 1 g, 2 g or 2 g by regimen) (label Table 2). For PD-associated peritonitis (ISPD 2022): intraperitoneal intermittent 1,000 mg daily; continuous loading dose 500 mg/L, then 125 mg/L in each exchange. Continuous cephalosporin doses may need about 25% more in patients with significant residual kidney function (ISPD 2022).
CRRT
Not in label. Li 2020 (Table 3): CVVH ultrafiltration 1,000 mL/h or less, 1 g every 8 hours; 1,500 mL/h or more, 2 g every 8 hours or 1 g every 6 hours; 30 mL/kg/h, 2 g every 8 hours as extended infusion. CVVHD dialysate 20–25 mL/kg/h, load 2 g, then 1.5–1.75 g every 8 hours. CVVHDF combined flow 1,000 mL/h or less, 1 g every 8 hours; 1,500 mL/h or more, 2 g every 8 hours or 1 g every 6 hours.
  • Dialyzable? Yes: about 68% removed during a 3-hour hemodialysis (label). For overdose the label advises hemodialysis, not peritoneal dialysis. Protein binding about 20%.
  • Monitoring CrCl for dose; neurotoxicity (encephalopathy, myoclonus, seizures, nonconvulsive status epilepticus), mainly with unadjusted doses in kidney impairment; stop cefepime if it occurs (label 5.2). Kidney function with aminoglycosides or loop diuretics.
Children (kidney dosing)
Show full dosing details
eGFR ≥60
Usual weight-based dose (CrCl >60) (label).
eGFR 30–59
No pediatric data; changes proportional to the adult table are recommended (label).
eGFR 15–29
No pediatric data; changes proportional to the adult table are recommended (label).
eGFR <15 (not on dialysis)
No pediatric data; changes proportional to the adult table are recommended (label).
Hemodialysis (intermittent)
No pediatric data; the label recommends changes proportional to the adult table (which includes hemodialysis). Specialist input.
Peritoneal dialysis
No pediatric data; the label recommends changes proportional to the adult table (which includes CAPD). Specialist input.
CRRT
No pediatric CRRT data in the cited sources. Specialist input.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

US label text: Renal impairment US FDA label

2.3 Dosage Adjustments in Patients with Renal Impairment Adult Patients Adjust the dose of cefepime for injection in patients with creatinine clearance less than or equal to 60 mL/min to compensate for the slower rate of renal elimination. In these patients, the recommended initial dose of cefepime for injection should be the same as in patients with CrCL greater than 60 mL/min except in patients undergoing hemodialysis.

The recommended doses of cefepime for injection in patients with renal impairment are presented in Table 2. When only serum creatinine is available, the following formula (Cockcroft and Gault equation) 1 may be used to estimate creatinine clearance. The serum creatinine should represent a steady state of renal function: Females: 0.85 x above value Table 2: Recommended Dosing Schedule for Cefepime for Injection in Adult Patients with Creatinine Clearance Less Than or Equal to 60 mL/min *On hemodialysis days, cefepime should be administered following hemodialysis.

Whenever possible, cefepime should be administered at the same time each day. Creatinine Clearance (mL/min) Recommended Maintenance Schedule Greater than 60 500 mg every 12 hours 1 g every 12 hours 2 g every 12 hours 2 g every 8 hours 30 to 60 500 mg every 24 hours 1 g every 24 hours 2 g every 24 hours 2 g every 12 hours 11 to 29 500 mg every 24 hours 500 mg every 24 hours 1 g every 24 hours 2 g every 24 hours Less than 11 250 mg every 24 hours 250 mg every 24 hours 500 mg every 24 hours 1 g every 24 hours Continuous Ambulatory Peritoneal Dialysis (CAPD) 500 mg every 48 hours 1 g every 48 hours 2 g every 48 hours 2 g every 48 hours Hemodialysis* 1 g on day 1, then 500 mg every 24 hours thereafter 1 g every 24 hours In patients undergoing Continuous Ambulatory Peritoneal Dialysis (CAPD), cefepime for injection may be administered at the recommended doses at a dosage interval of every 48 hours (see Table 2).

In patients undergoing hemodialysis, approximately 68% of the total amount of cefepime present in the body at the start of dialysis will be removed during a 3-hour dialysis period. The dosage of cefepime for injection for hemodialysis patients is 1 g on Day 1 followed by 500 mg every 24 hours for the treatment of all infections except febrile neutropenia, which is 1 g every 24 hours.

Cefepime for injection should be administered at the same time each day and following the completion of hemodialysis on hemodialysis days (see Table 2). Equation Pediatric Patients Data in pediatric patients with impaired renal function are not available; however, since cefepime pharmacokinetics are similar in adults and pediatric patients [see Clinical Pharmacology (12.3)], changes in the dosing regimen proportional to those in adults (see Tables 1 and 2) are recommended for pediatric patients.

8.6 Renal Impairment Adjust the dose of cefepime for injection in patients with creatinine clearance less than or equal to 60 mL/min to compensate for the slower rate of renal elimination [see Dosage Adjustments in Patients with Renal Impairment (2.3)].

Dosing: Pediatric

Approved ages
2 months up to 16 years (label).
Usual dose
Up to 40 kg: 50 mg/kg every 12 hours (every 8 hours for febrile neutropenia and P. aeruginosa pneumonia) (label).
Maximum dose
Not above the recommended adult dose (label).

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed
Pediatric use (US label) US FDA label

8.4 Pediatric Use The safety and effectiveness of cefepime in the treatment of uncomplicated and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin structure infections, pneumonia, and as empiric therapy for febrile neutropenic patients have been established in the age groups 2 months up to 16 years. Use of cefepime for injection in these age groups is supported by evidence from adequate and well-controlled studies of cefepime in adults with additional pharmacokinetic and safety data from pediatric trials [see Clinical Pharmacology (12.3)].

Safety and effectiveness in pediatric patients below the age of 2 months have not been established. There are insufficient clinical data to support the use of cefepime for injection in pediatric patients for the treatment of serious infections in the pediatric population where the suspected or proven pathogen is H. influenzae type b.

In those patients in whom meningeal seeding from a distant infection site or in whom meningitis is suspected or documented, an alternate agent with demonstrated clinical efficacy in this setting should be used.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Of the more than 6400 adults treated with cefepime for injection in clinical studies, 35% were 65 years or older while 16% were 75 years or older. When geriatric patients received the usual recommended adult dose, clinical efficacy and safety were comparable to clinical efficacy and safety in non-geriatric adult patients.

Serious adverse events have occurred in geriatric patients with renal insufficiency given unadjusted doses of cefepime, including life-threatening or fatal occurrences of the following: encephalopathy, myoclonus, and seizures [see Warnings and Precautions (5.2), Adverse Reactions (6.2)]. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.

Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and renal function should be monitored [see Clinical Pharmacology (12.3), Warnings and Precautions (5.2), Dosage and Administration (2.3)].

Administration

2.1 Dosage for Adults The recommended adult dosages and routes of administration are outlined in Table 1 below for patients with creatinine clearance greater than 60 mL/min. Administer cefepime for injection intravenously over approximately 30 minutes. Table 1: Recommended Dosage Schedule for Cefepime for Injection in Adult Patients with Creatinine Clearance (CrCL) Greater Than 60 mL/min * or until resolution of neutropenia. In patients whose fever resolves but who remain neutropenic for more than 7 days, the need for continued antimicrobial therapy should be re-evaluated frequently. ** Intramuscular route of administration is indicated only for mild to moderate, uncomplicated or complicated UTIs due to E. coli . § For P. aeruginosa , use 2 g IV every 8 hours. Site and Type of Infection Dose Frequency Duration (days) Adults Intravenous (IV)/ Intramuscular (IM) Moderate to Severe Pneumonia § 1 to 2 g IV Every 8 to 12 hours 10 Empiric therapy for febrile neutropenic patients 2 g IV Every 8 hours 7* Mild to Moderate Uncomplicated or Complicated Urinary Tract Infections, including pyelonephritis 0.5 to 1 g IV/IM** Every 12 hours 7 to 10 Severe Uncomplicated or Complicated Urinary Tract Infections, including pyelonephritis 2 g IV Every 12 hours 10 Moderate to Severe Uncomplicated Skin and Skin Structure Infections 2 g IV Every 12 hours 10 Complicated Intra-abdominal Infections § (used in combination with metronidazole) 2 g IV Every 8 to 12 hours 7 to 10

2.4 Preparation of Cefepime for Injection for Intravenous Infusion Vials Constitute the 1 gram or 2 grams vial, of cefepime for injection with the one of the following diluents: Sterile Water for Injection 0.9% Sodium Chloride Injection 5% Dextrose Injection 0.5% or 1% Lidocaine Hydrochloride Injection Sterile Bacteriostatic Water for Injection with Parabens or Benzyl Alcohol Dilute the reconstituted solution with one of the following compatible infusion solutions prior to intravenous infusion (Refer to Table 3 below for the amount of diluent to be added to each vial and the amount of the reconstituted solution to be withdrawn): 0.9% Sodium Chloride Injection 5% and 10% Dextrose Injection M/6 Sodium Lactate Injection 5% Dextrose and 0.9% sodium Chloride Injection Lactated Ringers and 5% Dextrose Injection Normosol ® -R and Normosol ® -M in 5% Dextrose Injection Parenteral drugs should be inspected visually for particulate matter before administration. If particulate matter is evident in reconstituted fluids, the drug solution should be discarded. Administer the resulting intravenous infusion over approximately 30 minutes. Intermittent intravenous infusion with a Y-type administration set can be accomplished with compatible solutions. However, during infusion of a solution containing cefepime, it is desirable to discontinue the other solution.

2.5 Preparation of Cefepime for Injection for Intramuscular Administration Constitute cefepime for injection vials 1 gram and 2 grams with one of the following diluents: Sterile Water for Injection, 0.9% Sodium Chloride, 5% Dextrose Injection, 0.5% or 1% Lidocaine Hydrochloride, or Sterile Bacteriostatic Water for Injection with Parabens or Benzyl Alcohol. Refer to Table 3 below for the amount of diluent to be added to each vial and the amount of reconstituted volume to be withdrawn. Parenteral drugs should be inspected visually for particulate matter before administration. If particulate matter is evident in reconstituted fluids, the drug solution should be discarded. Table 3: Preparation of Reconstituted Solutions of Cefepime for Injection Single-Dose Vials for Intravenous (IV)/ Intramuscular (IM) Administration Amount of Diluent to be added (mL) Approximate Cefepime Concentration (mg/mL) Amount of Reconstituted Volume to be Withdrawn (mL) Cefepime vial content 1 g (IV) 10 100 10.5 1 g (IM) 2.4 280 3.6 2 g (IV) 10 160 12.5

2.6 Compatibility and Stability Intravenous Cefepime for Injection Intravenous Infusion Compatibility Cefepime for injection vials are compatible at concentrations between 1 mg per mL and 40 mg per mL with the following intravenous infusion fluids: 0.9% Sodium Chloride Injection, 5% and 10% Dextrose Injection, M/6 Sodium Lactate Injection, 5% Dextrose and 0.9% Sodium Chloride Injection, Lactated Ringers and 5% Dextrose Injection, Normosol ® -R, and Normosol ® -M in 5% Dextrose Injection. These solutions may be stored up to 24 hours at controlled room temperature 20°C to 25°C (68°F to 77°F) or 7 days in a refrigerator 2°C to 8°C (36°F to 46°F). Admixture Compatibility Cefepime for injection admixture compatibility information is summarized in Table 4 . Table 4: Cefepime Admixture Stability NS = 0.9% Sodium Chloride Injection. D5W = 5% Dextrose Injection. na = not applicable. RT/L = Ambient room temperature and light. Cefepime for injection Concentration Admixture and Concentration Intravenous (IV) Infusion Solutions RT/L (20° to 25°C) Stability Time for Refrigeration (2° to 8°C) 40 mg/mL Amikacin 6 mg/mL NS or D5W 24 hours 7 days 40 mg/mL Ampicillin 1 mg/mL D5W 8 hours 8 hours 40 mg/mL Ampicillin 10 mg/mL D5W 2 hours 8 hours 40 mg/mL Ampicillin 1 mg/mL NS 24 hours 48 hours 40 mg/mL Ampicillin 10 mg/mL NS 8 hours 48 hours 4 mg/mL Ampicillin 40 mg/mL NS 8 hours 8 hours 4 to 40 mg/mL Clindamycin Phosphate 0.25 to 6 mg/mL NS or D5W 24 hours 7 days 4 mg/mL Heparin 10 to 50 units/mL NS or D5W 24 hours 7 days 4 mg/mL Potassium Chloride 10 to 40 mEq/L NS or D5W 24 hours 7 days 4 mg/mL Theophylline 0.8 mg/mL D5W 24 hours 7 days 1 to 4 mg/mL na Aminosyn™ II 4.25% with electrolytes and calcium 8 hours 3 days 0.125 to 0.25 mg/mL na Inpersol™ with 4.25% dextrose 24 hours 7 days Cefepime for Injection Admixture Incompatibility Do not add solutions of cefepime for injection to solutions of ampicillin at a concentration greater than 40 mg per mL, or to metronidazole, vancomycin, gentamicin, tobramycin, netilmicin sulfate, or aminophylline because of potential interaction. However, if concurrent therapy with cefepime for injection is indicated, each of these antibacterial drugs can be administered separately. Intramuscular Cefepime for Injection Cefepime for injection constituted as directed is stable for 24 hours at controlled room temperature 20ºC to 25ºC (68ºF to 77ºF) or for 7 days in a refrigerator 2ºC to 8ºC (36ºF to 46ºF) with the following diluents: Sterile Water for Injection, 0.9% Sodium Chloride Injection, 5% Dextrose Injection, Sterile Bacteriostatic Water for Injection with Parabens or Benzyl Alcohol, or 0.5% or 1% Lidocaine Hydrochloride. Intramuscular and Intravenous Cefepime for Injection As with other cephalosporins, the color of cefepime for injection powder, as well as its solutions tend to darken depending on storage conditions; however, when stored as recommended, the product potency is not adversely affected.

US FDA label

Dosage forms

Philippines

  • Powder for injection: 1 g, 1 g per vial, 1 mg, 1.0 g, 2 g, 500 mg
  • Powder for solution for injection: 1 g, 2 g
  • I g per vial powder for injection
  • Powder for injection (im/iv: 1 g

Registered products in the Philippines

103 products registered with the Food and Drug Administration (FDA) Philippines list Cefepime as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Cefepime (as hydrochloride (1 product) · Cefepime (as Hydrochloride) with Arginine (6 products) · Cefepime (as Hydrochloride) with Argine (1 product). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products103
Philippine FDA-registered products for Cefepime
Package insert
4-Gen 1000Cefepime (as hydrochloride)
1 g Powder for Injection (IM/IV)USP Type III Colorless Glass Vial with Rubber Stopper and Magenta Flip-Off Seal x 10 mL + FFS Sterile Water for Injection (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Stallion laboratories Pvt. Ltd.
DRP-3102-04
Jul 12, 2029
AccepimeCefepime (as hydrochloride)
1 gm Powder for Injection (I.M./I.V.)15 mL USP Type I transparent plain glass vial with 20 mm grey butyl rubber stopper and aluminum flip-off seal (Box of 1's)
Rx
Medisure Laboratories Pakistan Pvt LtdPakistan
Accesspoint International Trading Inc.Importer: Accesspoint International Trading, Inc.
DRP-14206
Jul 21, 2028
AlcemaxCefepime (as hydrochloride)
1 g Powder for Injection (IM/IV)USP Type III Colorless Glass Vial with rubber stopper and magenta flip-off seal x 10 mL + FFS Sterile Water for Injection (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Getz Pharma (Phils.), Inc.Importer: Ambica International CorporationTrader: Stallion laboratories Pvt. Ltd.
DRP-3102-03
Jul 12, 2029
AltamaxCefepime (as hydrochloride)
1 g Powder for Injection (I.M./I.V.)20 mL-capacity USP Type I colorless and transparent borosilicate glass vial sealed with chlorobutyl rubber stopper and green flip-off aluminum seal Box of 10's
Rx
Taiwan Biotech Co., Ltd.Taiwan
JustRight Healthcare Inc.
DR-XY43753
Sep 26, 2029
AxeraCefepime (as hydrochloride)
1 g Powder for Injection (IM/IV)USP Type I Clear Glass Vial with gray rubber stopper and orange/aluminum flip-off seal x 20 mL (Box of 1's and 10's + plastic tray); USP Type I Clear Glass Vial with gray rubber stopper and alucap orange (bronze) flip-off seal x 20 mL (Box of 1's and 10's + plastic tray)
Rx
PT Darya-Varia Laboratoria TbkIndonesia
UNILAB, Inc.
DR-XY41802
Mar 14, 2028
AxeraCefepime (as hydrochloride)
1 g Powder for Injection (IM/IV)USP Type I Clear Glass Vial with gray rubber stopper and orange/aluminum flip-off seal x 20 mL (Box of 1's and 10's + plastic tray); USP Type I Clear Glass Vial with gray rubber stopper and alucap orange (bronze) flip-off seal x 20 mL (Box of 1's and 10's + plastic tray)
Rx
PT Darya-Varia Laboratoria TbkIndonesia
UNILAB, Inc.
DRP-13911
Mar 14, 2028
AxeraCefepime (as hydrochloride)
2 g Powder for Injection (IM/IV)USP Type I Clear Glass Vial with gray rubber stopper and orange/aluminum flip-off seal or alucap orange (bronze) flip-off seal (Box of 1's; Box of 10's + plastic tray)
Rx
PT Darya-Varia Laboratoria TbkIndonesia
UNILAB, Inc.
DR-XY41803
Mar 14, 2028
AxeraCefepime (as hydrochloride)
2 g Powder for Injection (IM/IV)USP Type I Clear Glass Vial with gray rubber stopper and orange/aluminum flip-off seal or alucap orange (bronze) flip-off seal (Box of 1's; Box of 10's + plastic tray)
Rx
PT Darya-Varia Laboratoria TbkIndonesia
UNILAB, Inc.
DRP-13963
Mar 14, 2028
AxeraCefepime (as hydrochloride)
500 mg Powder for Injection (IM/IV)USP Type I Clear Glass Vial with Gray Rubber Stopper and Orange/Aluminum Flip-off Seal or Alucap Orange (Bronze) Flip-off Seal x 10 mL Box of 1's; Box of 10's + Plastic Tray
Rx
PT Darya-Varia Laboratoria TbkIndonesia
UNILAB, Inc.
DR-XY41801
Mar 14, 2028
BacefimeCefepime (as hydrochloride)
1g Powder for Injection (IM/IV)Transparent Borosilicate Glass Vial with Butyl Rubber Stopper and Aluminum Flip-Off Cap x l's (Box of 10's)
Rx
NCPC Hebei Huamin Pharmaceutical Company LimitedChina
GPC Geo Pharma Corporation
DRP-10893
Dec 14, 2026
BizapimeCefepime (as hydrochloride)
1 g Powder for Injection (IV/IM)20 mL Type I colorless glass vial with grey bromobutyl rubber stopper and green aluminum polypropylene flip-off cap (Box of 10's)
Rx
Laboratorio Reig Jofre S.A.Spain
Penta Labs Australia (Philippines)
DRP-10532
Oct 14, 2031
BizapimeCefepime (as hydrochloride)
2 g Powder for Injection (IM/IV)50 mL Type I colorless glass vial with grey bromobutyl rubber stopper and green aluminum polypropylene flip-off cap (Box of 10's)
Rx
Laboratorio Reig Jofre S.A.Spain
Penta Labs Australia (Philippines)
DRP-10533
Oct 14, 2031
BlefimeCefepime (as Hydrochloride)
1 g Powder for Injection (I.M./I.V.)USP Type I Clear Glass Vial w/ Grey Butyl Rubber Stopper X 10 mL (Box of 1's)
Rx
NCPC Hebei Huamin Pharmaceutical Co., Ltd.China
Vintel Med EnterprisesImporter: Aglobal Care, Inc.
DRP-5876-01
Apr 8, 2028
BonpimeCefepime (as hydrochloride)
1 g Powder for Injection (IM/IV20 mL USP Type III Clear Glass Vial with Grey Bromobutyl Rubber Stopper, Aluminum Seal, and Blue Flip-off Cap (Box of 1's)
Rx
Makcur Laboratories LimitedIndia
Penta Labs Australia (Philippines)Trader: Usquare Lifescience Pvt. Ltd.
DRP-16272
Jan 17, 2030
CefegenCefepime (as hydrochloride)
1 g per vial Powder for Injection (IM/IV)USP Type II Clear Glass Vial (Box of 1's) & 2 Ampoules of 5 mL Sterile Water for Injection as diluent
Rx
Neutro Pharma (Pvt.) Ltd.Pakistan
Genzen Pharmaceutical TradingImporter: Raquel-Abbas Pharmaceuticals & General Merchandise
DRP-10462-02
Mar 3, 2031
CefemarcCefepime (as hydrochlorideVariant spelling
1 g Powder for Injection (IM/IV)10 mL-capacity USP Type II clear colorless glass vial With butyl rubber stopper, aluminum seal and blue flip- off cap (Box of 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Marcburg Philippines Inc.
DR-XY49490
Sep 5, 2030
Cefenova-1000Cefepime (As Hydrochloride)
1 g Powder For Injection (I.M./I.V.)10 mL USP Type II glass vial with gray butyl rubber stopper, aluminum seal and blue flip-off cap (Box of l's and 10's)
Rx
Reyoung Pharmaceutical Co. Ltd.China
Medinova Pharmaceutical Inc.
DRP-10999
Dec 31, 2026
CefeproCefepime (as hydrochloride)
1 g Powder for Injection (IM/IV)15 mL USP Type III glass vial with 20mm grey butyl rubber stopper and 20mm colored flip off aluminum seal (Taxim Blue) (Box of 1’s)
Rx
Sance Laboratories Pvt. Ltd.India
Greencore Pharma Inc.
DRP-18398
Jun 30, 2031
CeferpimCefepime (as hydrochloride) with ArginineVariant spelling
1 g Powder for Solution for Injection (IM/IV)Store at temperatures not exceeding 30°C. Protect from light.
Rx
Reyoung Pharmaceutical Co., Ltd.China
Sanimed Pharmaceuticals Inc.
DRP-18729
Aug 27, 2031
CefesaveCefepime Hydrochloride
2 g Powder for Injection (I.M./I.V)USP Type I Clear Glass Vial x 20 mL (Box of 1's)
Rx
Yeluri Formulations Pvt. Ltd.India
Savelink Pharma and Trading Co.Importer: Medinova Pharmaceutical Inc.
DRP-3387-04
Aug 9, 2028
CefevexCefepime
1g Powder for Injection (IM/IV)Type II Mould Vial (Box of 10's Packed Individually)
Rx
Reyoung Pharmaceutical Co., Ltd.China
SANNOVEX PHARMACEUTICAL DISTRIBUTOR
DR-XY42232
Jul 15, 2028
CefevexCefepime Hydrochloride
1g Powder For Solution for Injection (IM/IV)10 mL-capacity clear glass vial with rubber stopper and aluminum plastic cap + clear glass ampoule x 10 mL for sterile water for injection (as diluent) (in one box) 10 mL-capacity clear glass vial with rubber stopper and aluminum plastic cap (Box of 10's)
Rx
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China
Sannovex Pharmaceutical Distributor
DR-XY49721
Jun 2, 2031
Ceficad 1000Cefepime (as hydrochloride)
1g Powder for Injection (IM/IV)USP Type III Flint Glass Vial (Box of 1's)
Rx
Cadila Pharmceuticals LimitedIndia
Importer: BIOCARE LIFESCIENCES, INC.
DRP-12038
Jun 26, 2029
Cefimed 1000Cefepime(As Hydrochloride)
1 g Powder for Injection (IM/IV)Type I Flint Glass Vial with Gray Bromobutyl Rubber Stopper and Yellow Aluminum Flip-Off Seal Cap xe l's (Box of 1's)
Rx
Yeluri Formulations Pvt. Ltd.India
Importer: Medinova Pharmaceutical, Inc.
DRP-10889
Dec 14, 2026
CeflozylCefepime (as hydrochloride)
1g Powder for Injection (IM/IV)20mL-Capacity Type III Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Aluminum Seal with Flip-Off Cap x 1mL + 10mL Sterile Water for Injection in Type I Clear Glass Ampoule (Diluent) (Box of 1's)
Rx
Vellinton HealthcareIndia
Pranish Inc.
DR-XY49754
Jun 18, 2031
Cefpime 1000Cefepime (as hydrochloride with arginine)
1g Powder for Solution for Injection (IM/IV)20 mL-capacity USP Type III clear glass vial with rubber stopper and aluminum flip-off seal + plastic ampoule x 10 mL for sterile water for injection (diluent) (Box of 1's)
Rx
Innova Captab Ltd.India
Airlife International Trading Corporation
DRP-17516
Jan 16, 2031
CemoxiCefepime (as hydrochloride)
2 g Powder for Injection (IM/IV)USP Type I clear glass vial, with grey chlorobutyl rubber stopper, aluminum seal and blue flip-off cap. (Box of 10's)
Rx
Hankook Korus Pharm. Co., Ltd.Korea
H & B Pharma International Inc.Trader: Union Korea Pharm Co.,
DRP-16056
Oct 29, 2029
Centrapime-500Cefepime (as hydrochloride)
500 mg Powder for Injection (IM/IV)10 mL-capacity USP Type I Clear Glass Vial with Gray Bromobutyl Rubber Stopper (Box of 1's)
Rx
Swiss Parenterals Ltd.India
Central West Medicale Inc.Importer: Medinova Pharmaceutical Inc.
DRP-13431-01
Feb 17, 2028
CepefilCefepime (as hydrochloride)
1 g Powder for Injection (IM/IV)USP Type III Colorless Glass Vial with rubber stopper and magenta flip-off seal x 10 mL + FFS Sterile Water for Injection Box of 1's
Rx
Inject Care Parenterals Pvt. Ltd.India
Vintel Med EnterprisesImporter: Ambica International CorporationTrader: Stallion laboratories Pvt. Ltd.
DRP-3102-02
Jul 12, 2029
CephalexCefepime (as hydrochloride)
1 g Powder for Injection (IM/IV)15 mL-capacity USP Type I Clear Vial with grey bromobutyl rubber stopper with aluminum flip-off seal and olive green cap (Box of 1's)
Rx
Swiss Parenterals Ltd.India
A-Z Market Enterprise Developers Inc.
DR-XY48160
Jul 20, 2027
CepimedCefepime (as hydrochloride)
1 g Powder for Injection (IM/IV)20 mL USP Type III clear and colorless glass vial sealed with bromobutyl rubber stopper and magenta flip-off seal (Box of 1's)
Rx
Zeiss Pharmaceuticals Pvt. Ltd.India
Ranixx PharmaceuticalsImporter: Sanimed Pharmaceuticals Inc.
DRP-7125-03
Mar 29, 2027
CepiramCefepime (as hydrochloride)
1 g Powder for Injection (IM/IV)USP Type II Glass Vial with Film-Coated Bromobutyl Rubber Stopper and Aluminum-Plastic Combined Cap x 10 mL (Box of 1's)
Rx
Qilu Pharmaceutical Co. Ltd.China
The Cathay Drug Co., Inc.
DR-XY49120
Jul 4, 2029
CepiramCefepime (as Hydrochloride)
1 g Powder for Injection (IM/IV)USP Type III Colorless Glass Vial with rubber stopper and magenta flip-off seal x 10 mL + FFS Sterile Water for Injection (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
The Cathay Drug Co., Inc.Importer: Ambica International CorporationTrader: Stallion laboratories Pvt. Ltd.
DRP-3102-06
Jul 12, 2029
CepiramCefepime (as hydrochloride)
1 g Powder for Injection (IM/IV)Type I clear and colorless glass vial Box of 1's
Rx
Zeiss Pharmaceuticals Pvt. Ltd.India
The Cathay Drug Co., Inc.Importer: Baxter Healthcare Philippines Inc.Trader: Baxter Pharmaceuticals India Private Limited
DRP-6588-01
Apr 18, 2028
CyfepimeCefepime (as hydrochloride)
1 g Powder for Injection (I.M./I.V.)Tubular glass vial, sealed with rubber stopper and capped with aluminum-plastics combination caps in monocarton (Box of 10’s)
Rx
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China
AMB HK Enterprises Inc.
DRP-8376
Sep 18, 2029
DecextremeCefepime Hydrochloride
1 g Powder For Solution For Injection (IM/IV)15 mL-capacity TYpe IIII Glass Vial Sealed with Bromobutyl Rubber Stoppper with Aluminum Seal and Flip-off cap x 1's (Box of 1's)
Rx
Ananta Medicare LimitedIndia
Ambica International Corporation
DRP-18791
Sep 8, 2031
DecextremeCefepime Hydrochloride
2 g Powder For Solution For Injection (IM/IV)20 mL -capacity Type III Glass Vial Sealed with Bromobutyl Rubber Stopper with Aluminum Seal and Flip-off Cap x 1's (Box of 1's)
Rx
Ananta Medicare LimitedIndia
Ambica International Corporation
DRP-18792
Sep 8, 2031
DeltacefCefepime (as hydrochloride)
1 g Powder for Injection (IM/IV)15 mL-capacity Type I borosilicate clear glass vial with grey bromobutyl rubber stopper and aluminum cap (Box of 1's)
Rx
Medochemie (Far East) Ltd., (Aseptic Cephalosporin Facility)Vietnam
Detoxicare Philippines, Inc.
DRP-11920
May 20, 2027
DivipimeCefepime (as Hydrochloride)
1 g Powder for Injection (I.M./I.V.)20 mL-Type I Glass Vial Sealed with Grey Butyl Rubber Plug and Pink Flip Off Seal Cap x 1's (Box of 1's)
Rx
Venus Remedies LimitedIndia
Divjot Enterprises Corp.
DR-XY49188
Aug 29, 2029
FepimCefepime (as hydrochloride)
1 g Powder for Injection (IM/IV)USP Type I Clear Colorless Glass Vial Box of 1's
Rx
Yeluri Formulations Pvt. Ltd.India
Labmate Pharma Inc.Importer: Suhitas Pharmaceuticals Inc.Trader: Sherrington Pharmaceuticals Pvt. Ltd.
DRP-3828
Jul 9, 2027
Fepimed-1Cefepime (as hydrochloride)
1 g Powder for Injection (IV)10 mL USP Type II Clear Glass Vial with Grey Butyl Rubber Stopper and Blue Flip-Off Cap (Box of 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Dreamax Incorporated
DRP-15644
Aug 14, 2029
Fepimed-1 PlusCefepime (as hydrochloride)
1 g Powder for Injection (IV)10 mL USP Type II Clear Glass Vial Sealed with Grey Butyl Rubber Stopper and Blue Flip-Off Cap x 1's+ USP Type I Clear Glass Ampoule x 10 mL containing Sterile Water for Injection (as diluent)
Rx
Reyoung Pharmaceutical Co., LtdChina
Dreamax Incorporated
DRP-15772
Sep 20, 2029
ForcefCefepime (as hydrochloride)
1 g Powder for Injection (I.M./I.V.)20 mL Capacity USP Type III Clear and Colorless Glass Vial with Grey Bromo Butyl Rubber Stopper and White Colored Flip-off Seal Box of 1's
Rx
Theon Pharmaceuticals LimitedIndia
HEXAGON PHARMACEUTICALS
DR-XY46816
Jan 24, 2030
GlobalpimeCefepime (As Hydrochloride)
1.0 g Powder for Injection (I.V./I.M.)USP Type II Colorless and Transparent Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Aluminum Blue Flip-off Plastic Cap in Monocarton (Box of 10's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
First Global Trading Corporation
DRP-11938
May 20, 2027
GofimeCefepime (as hydrochloride)
1g Powder for Injection (I.M./I.V)10 mL USP Type II glass vial with gray butyl rubber stopper, aluminum seal and blue flip-off cap (Box of 1's and 10's)
Rx
Reyoung Pharmaceutical Co. Ltd.China
Applied Pharmaceutical Distribution Inc.Importer: Medinova Pharmaceutical Inc.
DRP-10999-02
Dec 31, 2026
GofimeCefepime hydrochloride
2 g Powder for Injection (I.M./I.V)USP Type I Clear Glass Vial x 20 mL (Box of 1's and 10's)
Rx
Yeluri Formulation Pvt. Ltd.India
APPLIED PHARMACEUTICAL DISTRIBUTION INC.Importer: Medinova Pharmaceutical Inc.
DRP-3387-02
Aug 9, 2028
GofimeCefepime (as hydrochloride)
2 g Powder for Injection (IM/IV)20 mL-capacity USP Type 1 clear and colorless glass vial (Box of 1's)
Rx
Yeluri Formulations Pvt. LtdIndia
Applied Pharmaceutical Distribution Inc.Importer: Suhitas Pharmaceuticals Inc.Trader: Sherrington Pharmaceuticals Pvt. Ltd.
DRP-3830-01
Jul 9, 2027
HapimaxCefepime (as hydrochloride) with ArginineVariant spelling
1 g Powder for Injection (I.M./I.V.)1 g vial in individual boxes (Box of 10's)
Rx
Harbin Pharmaceutical Group Co., Ltd General Pharm. FactoryChina
Endure Medical Inc.
DRP-16400
Jan 18, 2031
HapimaxCefepime (as Hydrochloride) with ArginineVariant spelling
500 mg Powder for Injection (IM/IV)USP Type I Clear vials with rubber stopper and blue flip-off seal individually boxed (Box of 10's)
Rx
Harbin Pharmaceutical Group Co., Ltd. General Pharm. FactoryChina
Endure Medical, Inc.
DR-XY34471
Apr 18, 2028
HapimaxCefepime (as Hydrochloride) with ArginineVariant spelling
500 mg Powder for Injection (IM/IV)USP Type I Clear vials with rubber stopper and blue flip-off seal individually boxed (Box of 10's)
Rx
Harbin Pharmaceutical Group Co., Ltd. General Pharm. FactoryChina
Endure Medical, Inc.
DRP-16401
Apr 18, 2028
IvipimeCefepime (as hydrochloride)
1 g Powder for Injection (IV)20 mL USP Type I Flint Glass Vial with Grey Rubber Stopper and Aluminum Flip-Off Seal (Box of 1's)
Rx
VHB Medi Sciences LimitedIndia
Bliss Pharma Distribution and Consultancy
DRP-15771
Sep 20, 2029
LuopimeCefepime (as hydrochloride)
1 g Powder for Injection (IM/IV)15 mL-capacity Low Borosilicate glass vial sealed with bromobutyl rubber stopper and aluminum-plastic cap in a box
Rx
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.China
Door 2 Dacota Holdings Inc
DRP-16444
Mar 13, 2030
MaxefCefepime (as Hydrochloride)
1 g Powder for Injection (IM/IV)Clear USP Type I Glass Vial x 15mL plus USP Type I Clear Glass Ampoule of Sterile Water for Injection 5 mL (as Diluent) (Box of 1 Vial and 1 Ampoule)
Rx
Geofman PharmaceuticalsKarachi Pakistan
Sahar International Trading Inc.
DRP-7681
Oct 26, 2031
MedifimeCefepime (as hydrochloride)
1 g Powder for Injection (IM/IV)20 mL-capacity USP Type III clear glass vial with rubber stopper and aluminum orange flip-off seal and glass ampoule x 10mL (diluent) (Box of 1's)
Rx
Finebiotics Pharma LtdIndia
Medinova Pharmaceuticals Inc.
DRP-16145
Nov 13, 2029
Medifime-2Cefepime (as Hydrochloride)
2g Powder for Injection (IM/IV)20 mL-capacity USP Type III glass vial with grey butyl rubber stopper, aluminum seal and green flip-off cap (Box of 1's)
Rx
Ananta Medicare LimitedIndia
Medinova Pharmaceutical Inc
DRP-18521
Jul 27, 2031
Megapime HospiCefepime (As Hydrochloride)
1 g Powder for Injection (I.M/I.V)USP Type I Clear Glass Vial w/ Grey Butyl Rubber Stopper and Aluminum Cap with Blue Colored Plastic Flip-off Seal X 10 mL (Box of 1's)
Rx
NCPC HEBEI HUAMIN PHARMACEUTICAL CO., LTD.China
ALKEM LABORATORIES CORPORATIONImporter: AGLOBAL CARE, INC.
DRP-5876-02
Apr 8, 2028
MofixemCefepime (as hydrochloride)
1 g Powder for Injection (I.M./I.V.)10-mL transparent and colorless USP type II glass vial sealed with gray halogenated butyl rubber stopper and blue flip-off cap (Box of 10's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Philgen Pharmaceuticals Inc
DRP-15148
May 14, 2029
MyfepCefepime (as hydrochloride)
1 g Powder for Injection (IM/IV)20 mL-capacity USP Type III clear and colorless glass vial with grey bromobutyl rubber stopper and aluminum. seal with red flip-off cap (Box of 1's)
Rx
Makcur Laboratories LimitedIndia
Afree Pharmaceutical Distribution Corp.
DRP-14121
Jun 23, 2028
NeupimeCefepime (as hydrochloride)
I g per vial Powder for Injection (IM/IV)USP Type II Clear Glass Vial (Box o f 1 's) & 2 Ampoules o f 5 mL Sterile Water for Injection as diluent
Rx
Neutro Pharma (Pvt.) Ltd.Pakistan
Raquel-Abbas Pharmaceuticals & General Merchandise
DRP-10462
Mar 3, 2031
NoneCefepime (as hydrochloride)
1 g Powder for Injection (IM/IV)USP Type I Clear Glass Vial with gray rubber stopper and orange/aluminum flip-off seal x 20 mL (Box of 1's and 10's + plastic tray)
Rx
PT Darya-Varia Laboratoria TbkIndonesia
RiteMED Phils., Inc.Importer: UNILAB, Inc.
DRP-13911-01
Mar 14, 2028
NoneCefepime (as hydrochloride)
1 g Powder for Injection (IM/IV)USP Type III Colorless Glass Vial with Rubber Stopper and Magenta Flip-off Seal x 10 mL + FFS Sterile Water for Injection (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Diafarm Inc.Importer: Ambica International CorporationTrader: Stallion laboratories Pvt. Ltd.
DRP-3102-05
Jul 12, 2029
NoneCefepime (as hydrochloride)
2 g Powder for Injection (IM/IV)USP Type I Clear Glass Vial with gray rubber stopper and orange/aluminum flip-off seal or alucap orange (bronze) flip-off seal (Box of 1's; Box of 10's + plastic tray)
Rx
PT Darya-Varia Laboratoria TbkIndonesia
Ritemed Phils., Inc.Importer: UNILAB, Inc.
DRP-13963-01
Mar 14, 2028
NoneCefepime (as Hydrochloride) with ArginineVariant spelling
500 mg Powder for Injection (IM/IV)USP Type I Clear vials with rubber stopper and blue flip-off seal individually boxed (Box of 10's)
Rx
Harbin Pharmaceutical Group Co., Ltd. General Pharm. FactoryChina
Phil. Pharmawealth, Inc.Importer: Endure Medical, Inc.
DRP-16401-01
Apr 18, 2028
NovafimeCefepime (As Hydrochloride)
1g Powder For Injection (IM/IV)Type I Clear Glass Vial with Gray Bromobutyl Rubber Stopper and Green Aluminum Flip-Off Seal Cap x l's (Box of l's)
Rx
Swiss Parenterals Ltd.India
Medinova Pharmaceutical, Inc.
DRP-11018
Jan 18, 2027
NovafimeCefepime (as Hydrochloride)
500mg Powder for Injection (I.M./I.V.)10 mL-capacity USP Type I Clear Glass Vial with Gray Bromobutyl Rubber Stopper [Box of 1's]
Rx
Swiss Parenterals Ltd.India
Medinova Pharmaceutical Inc.
DRP-13431
Feb 17, 2028
OfipimeCefepime (as hydrochloride)
1g Powder for Injection (I.M./I.V.)USP Type III Clear and Colorless Glass Vial x 20mL (Box of 1’s)
Rx
Inject Care Parenterals Pvt. Ltd.India
Orange Biotec, Inc.Importer: Suhitas Pharmaceuticals, Inc.Trader: Mac Heal Laboratories Ltd.
DRP-3266-02
Sep 21, 2031
OrapimeCefepime (as hydrochloride)
1 g Powder for Injection (IM/IV)USP Type III Clear and Colorless Glass Vial x 20 mL (Box of 1’s)
Rx
Inject Care Parenterals Pvt. Ltd.India
Orange Biotec Inc.Importer: Suhitas Pharmaceuticals Inc.Trader: Mac Heal Laboratories Ltd.
DRP-3266-01
Sep 21, 2031
Pime-MaxCefepime (as hydrochloride)
1 g Powder for Injection (IM/IV)USP Type III Clear Glass Vial + 10 mL USP Type III Clear Ampoule Box of 1 Vial + Diluent
Rx
Zazen Pharma Pvt. Ltd.India
I.E. Medica, Inc.Trader: Stratgen Pharma Pvt. Ltd.
DRP-2222
Jun 2, 2030
ProcefepCefepime (as hydrochloride)
1g Powder for Injection (IM/IV)USP Type III clear and colorless glass vial sealed with bromobutyl rubber stopper and magenta flip-off seal x 20mL Box of 1's
Rx
Zeiss Pharmaceuticals Pvt. Ltd.India
Ellebasy Medicale Group Inc.Importer: Sanimed Pharmaceuticals Inc.
DRP-7125-02
Mar 29, 2027
RovatimCefepime Hydrochloride
2 g Powder for Injection (I.M./I.V)USP Type I Clear Glass Vial x 20 mL (Box of 1's); USP Type I Clear Glass Vial x 20 mL (Box of 10's)
Rx
Yeluri Formulation Pvt. Ltd.India
Medinova Pharmaceutical Inc.
DRP-3387
Aug 9, 2028
Sanocef 1000Cefepime (as hydrochloride)
1 g Powder for Injection (I.M./I.V.)USP Type III clear glass vial with grey butyl rubber stopper and flip off seal Box of 1’s
Rx
Sance Laboratories Pvt. Ltd.India
AMB HK Enterprises Inc.
DRP-8400
Sep 25, 2029
SanopimeCefepime (as hydrochloride)
1 g Powder for Injection (IM/IV)20 mL USP Type III clear and colorless glass vial sealed with bromobutyl rubber stopper and magenta flip-off seal (Box of 1's)
Rx
Zeiss Pharmaceuticals Pvt. Ltd.India
Sanimed Pharmaceuticals Inc.
DRP-7125
Mar 29, 2027
Sanpime 1000Cefepime (as hydrochloride)
1 g Powder for Injection (IM/IV)20 mL USP Type III clear and colorless glass vial sealed with bromobutyl rubber stopper and magenta flip-off seal (Box of 1's)
Rx
Zeiss Pharmaceuticals Pvt. Ltd.India
Oro Sinai Pharma and General Merchandise, Inc.Importer: Sanimed Pharmaceuticals Inc.
DRP-7125-01
Mar 29, 2027
SaphipimeCefepime (as hydrochloride)
1 gram Powder for Injection (I.V./I.M.)USP Type I Flint Glass Vial with Gray Bromo Butyl Rubber Stopper and Aluminum Taxim Blue Flip-off Seal (Box of 1's and 10's)
Rx
Kilitch Drugs (India) Ltd.India
Nelpa Lifesciences, Inc.
DRP-12262
Jul 6, 2027
Seabact-1000Cefepime Hydrochloride
1 g Powder for Injection (IV)15mL-capacity Type I Flint Glass Vial Sealed with Grey Butyl Rubber Stopper and Yellow Coloured Flip-off Seal (Box of 1's)
Rx
Yeluri Formulations Pvt. Ltd.India
Seapharma International, Inc.
DRP-11413
Apr 25, 2027
Seabact-2000Cefepime (as hydrochloride)
2g Powder for Injection (IV)20mL-capacity Type I Flint Glass Vial with Grey Butyl Rubber Stopper and Green Colored Aluminum Flip-off Seal (Box of 1's)
Rx
Yeluri Formulations Pvt. Ltd.India
Seapharma International, Inc.
DRP-11412
Apr 25, 2027
Sefepi 1000Cefepime (as Hydrochloride)
1 g Powder for Injection (I.M./I.V.)USP Type III glass vial x 20 mL (Box of 1’s)
Rx
Sakar Healthcare Pvt. Ltd.India
Macropharma Corporation
DRP-12461
Aug 11, 2027
SefepimCefepime (as hydrochloride)
1 g Powder for Injection (IM/IV)15 mL USP Type I clear glass vial+ 10 mL ampoule of Sterile Water for Injection as diluent per box
Rx
Nectar Lifesciences LimitedIndia
Hovid Inc.Trader: Hovid Berhad
DR-XY46197
Dec 13, 2027
SefpimeCefepime
1g Powder for InjectionUSP Type I Glass Vial Packed in Monocarton x 15mL (Box of 10's)
Rx
Sinopharm Zhijun (Shenzhen) Pharmaceutical Co., Ltd.China
Dynasty Pharmaceuticals
DRP 8489
Jun 23, 2031
SefpimeCefepime (as hydrochloride)
2g Powder for Injection (I.V./I.M.)30mL - capacity Type III Clear and Colorless Glass Vial with Chlorobutyl Rubber Stopper and Aluminum Seal with Red Flip-off cap (Box of 10 vials in Individual cartons)
Rx
Sinopharm Zhijun (Shenzhen) Pharmaceutical Co., Ltd.China
Dynasty Pharmaceuticals
DRP-10023
Nov 21, 2027
SepimeCefepime (as hydrochloride)
1 g Powder for Injection (I.M/I.V)USP Type I Clear Glass Vial w/ Grey Butyl Rubber Stopper and Aluminum Cap with Blue Colored Plastic Flip-off Seal X 10 mL (Box of 1's)
Rx
NCPC HEBEI HUAMIN PHARMACEUTICAL CO., LTD.China
AGLOBAL CARE, INC.
DRP-5876
Apr 8, 2028
Sherpime-1000Cefepime (as Hydrochloride)
1g Powder for Injection (IM/IV)Type I Flint Glass Vial Sealed with Grey Butyl Rubber Stopper and Yellow Colored Flip-off Seal (Box of 10's) (Box of 10's)
Rx
Yeluri Formulations Pvt. Ltd.India
Pharma-Surrey International, Inc.
DRP-9150
Sep 18, 2030
SolpimeCefepime (as hydrochloride)
1 g Powder for Injection (I.M/I.V)USP Type I Clear Glass Vial w/ Grey Butyl Rubber Stopper and Aluminum Cap with Blue Colored Plastic Flip-off Seal X 10 mL (Box of 1's)
Rx
NCPC Hebei Huamin Pharmaceutical Co., Ltd.China
Solvire Life IncorporatedImporter: Aglobal Care, Inc.
DRP-5876-03
Apr 8, 2028
SpectraxCefepime (as Hydrochloride)
1g Powder for Injection (IM/IV)Type I clear and colorless glass vial (Box of 1's)
Rx
Zeiss Pharmaceutical Pvt. Ltd.India
Baxter Healthcare Philippines Inc.Trader: Baxter Pharmaceuticals India Private Limited
DRP-6588
Apr 18, 2028
StafipimeCefepime (as hydrochloride)
1 g Powder for Injection (IM/IV)USP Type III Colorless Glass Vial with rubber stopper and magenta flip-off seal x 10 mL + FFS Sterile Water for Injection (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Marketzone Inc.Importer: Ambica International CorporationTrader: Stallion laboratories Pvt. Ltd.
DRP-3102
Jul 12, 2029
StarpimeCefepime (as hydrochloride)
1 g Powder for injection (I.M./I/V.)USP Type III clear colorless glass vial (Box of 1's)
Rx
Celogen Pharma Pvt. Ltd.India
Pharmastar International Trading Corp.
DRP-7014
Mar 4, 2031
SupimeCefepime (as hydrochloride)
1 g Powder for Injection (IM/IV)USP Type III Clear and Colorless Glass Vial x 20 mL (Box of 1’s)
Rx
Inject Care Parenterals Pvt. Ltd.India
Uni-Pharma Phils., Inc.Importer: Suhitas Pharmaceuticals Inc.Trader: Mac Heal Laboratories Ltd.
DRP-3266
Sep 21, 2031
SupimeCefepime (as hydrochloride)
2 g Powder for Injection (IM/IV)20 mL-capacity USP Type 1 clear and colorless glass vial (Box of 1's)
Rx
Yeluri Formulations Pvt. Ltd.India
Importer: Suhitas Pharmaceuticals Inc.Trader: Sherrington Pharmaceuticals Pvt. Ltd.
DRP-3830
Jul 9, 2027
TerrapimeCefepime Hydrochloride
2 g Powder for Injection (I.M./I.V.)USP Type I Clear Glass Vial x 20 mL (Box of 1's & 10's)
Rx
Yeluri Formulations Pvt. Ltd.India
Santerra TradingImporter: Medinova Pharmaceutical Inc.
DRP-3387-03
Aug 9, 2028
Totacef-1000Cefepime (as hydrochloride) (with L-Arginine)
1 g Powder for Injection (I.M./I.V.)20 mL-capacity USP Type I clear and colorless glass vial with grey bromobutyl rubber stopper and aluminum seal with magenta flip-off cap (Box of 1's)
Rx
Mankind Pharma Limited (Unit-1)India
Ambica International Corporation
DRP-13716
Mar 30, 2028
UNIPIMCefepime (as hydrochloride)
1 mg Powder for Injection (I.M./I.V.)15 mL USP Type I Clear Glass Vial + 10 mL Clear Glass Ampoule (Diluent) Water for Injection in Blister Tray Box of 1's
Rx
Drug International LimitedBangladesh
JAZMARK PHARMACEUTICAL
DR-XY42807
Oct 14, 2028
Unipime 1gCefepime (hydrochloride)
1 g Powder for Injection (IV/IM)USP Type I Borosilicate Clear Glass Vial With Grey Chlorobutyl Rubber Stopper Sealed with Aluminum and Orange Flip Cap (Box of 10's); USP Type I Borosilicate Clear Glass Vial with Grey Chlorobutyl Rubber Stopper Sealed with Aluminum and Orange Flip Cap (Box of 1's)
Rx
Union Korea Pharm Co., Ltd.Republic of Korea
Uni-Pharma Phils., Inc.Importer: H & B Pharma International Inc.
DRP-9034
Aug 13, 2030
UrecefCefepime (as hydrochloride)
2 g Powder for Injection (I.M./I.V.)USP Type II Glass Vial (Box of 10's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Endure Medical, Inc.
DR-XY45060
Feb 11, 2031
UrecefCefepime (as hydrochloride)
500mg Powder for Injection (I.M./I.V.)USP Type II Clear Glass Vial Box of 10's
Rx
REYOUNG PHARMACEUTICAL CO., LTD.China
ENDURE MEDICAL, INC.
DR-XY46570
May 21, 2029
Welzpime 1000Cefepime (as hydrochloride)
1g Powder for Injection (IM/IV)Type III Clear Glass Vial sealed with Rubber Stopper and Aluminum Seal with Green Flip-Off Cap x 1's + 10mL Sterile Water for Injection in LDPE Ampoule Box of 1's)
Rx
Malik Lifesciences Pvt. Ltd.India
SMHP Marketing & ConsultancyTrader: Unosource Pharma Ltd.
DRP-16917
Aug 20, 2030
ZEFAROXCefepime (as hydrochloride)
1 g Powder for Injection (I.M./1.V.)Tubular glass vial, sealed with rubber stopper and capped with aluminium-plastics combination caps in monocarton Box of 10'S
Rx
CSPC Zhongnuo Pharmaceutical (Shijianzhuang) Co. Ltd.China
PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc.
DRP-8376-02
Sep 18, 2029
ZefegenCefepime (as hydrochloride)
1 g Powder for Injection (I.M./I.V)10 mL USP Type II glass vial with gray butyl rubber stopper, aluminum seal and blue flip-off cap (Box of 1's and 10's)
Rx
Reyoung Pharmaceutical Co. Ltd.China
GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutical Inc.
DRP-10999-01
Dec 31, 2026
ZepimCefepime (as hydrochloride)
1 g powder for injectionUSP Type I colorless glass vial x 1's (Box of 1's)
Rx
Kyongbo Pharmaceutical Co., Ltd.Republic of Korea
PharmAsia-Cuvest, Incorporated
DR-XY41478
Dec 18, 2027
ZepimeCefepime (as Hydrochloride)
1 g Powder for Injection (I.M./I.V.)Clear colorless glass vial with rubber stopper and light green flip-off aluminum seal (Box of 10's)
Rx
Singapore Pharmawealth Lifesciences, Inc.Philippines
—
DR-XY36676
Sep 22, 2029
ZepimeCefepime (as hydrochloride) with ArginineVariant spelling
1 g Powder for Injection (I.M./I.V.)1 g vial in individual boxes (Box of 10's)
Rx
Harbin Pharmaceutical Group Co., Ltd. General Pharm. FactoryChina
Phil. Pharmawealth, IncImporter: Endure Medical, Inc.
DRP-16400-01
Feb 7, 2032
ZepimeCefepime (as Hydrochloride)
2g Powder for Injection (I.M./I.V.)Clear colorless glass vial with light green flip-off seal (Box of 10's)
Rx
Singapore Pharmawealth Lifesciences, Inc.Philippines
—
DR-XY36674
Sep 18, 2029
ZepimeCefepime (as hydrochloride)
500 mg Powder for Injection (I.M./I.V.)USP Type I Glass Vial with orange flip-off seal + 5 mL diluent Box of 1's
Rx
Singapore Pharmawealth Lifesciences, Inc.Philippines
—
DR-XY37533
Jan 4, 2029
(no brand name)Cefepime (as Hydrochloride) with ArgineVariant spelling
1g Powder For Injection (IM/IV)Clear glass vial type III with grey butyl rubber stopper with blue flip-off aluminum cap (Box of 10's)
Rx
NCPC Hebei Huamin Pharmaceutical Company LimitedChina
Kwanstar Pharma Distributor
DRP-12418
Aug 4, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Cefepime for Injection, USP is a sterile white to pale yellow powder of cefepime in single-dose vials and it is available in the following strengths: 1 gram per vial 2 grams per vial Cefepime for Injection is a sterile powder of cefepime in single-dose vials for reconstitution, available in the following strengths: 1 gram per vial. (3) 2 grams per vial. (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Hypersensitivity Reactions: Cross-hypersensitivity among beta-lactam antibacterial drugs may occur in up to 10% of patients with a history of penicillin allergy. If an allergic reaction to cefepime for injection occurs, discontinue the drug. (5.1)
  • Neurotoxicity: May occur especially in patients with renal impairment administered unadjusted doses. If neurotoxicity associated with cefepime for injection therapy occurs, discontinue the drug. (5.2)
  • Clostridioides difficile -Associated Diarrhea (CDAD): Evaluate if diarrhea occurs. (5.3)
5.1 Hypersensitivity Reactions

5.1 Hypersensitivity Reactions Before therapy with cefepime for injection is instituted, careful inquiry should be made to determine whether the patient has had previous immediate hypersensitivity reactions to cefepime, cephalosporins, penicillins, or other beta-lactams. Exercise caution if this product is to be given to penicillin-sensitive patients because cross-hypersensitivity among beta-lactam antibacterial drugs has been clearly documented and may occur in up to 10% of patients with a history of penicillin allergy.

If an allergic reaction to cefepime for injection occurs, discontinue the drug and institute appropriate supportive measures.

5.2 Neurotoxicity

5.2 Neurotoxicity Serious adverse reactions have been reported including life-threatening or fatal occurrences of the following: encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor, and coma), aphasia, myoclonus, seizures, and nonconvulsive status epilepticus [see Adverse Reactions (6.2)]. Most cases occurred in patients with renal impairment who did not receive appropriate dosage adjustment.

However, some cases of neurotoxicity occurred in patients receiving a dosage adjustment appropriate for their degree of renal impairment. In the majority of cases, symptoms of neurotoxicity were reversible and resolved after discontinuation of cefepime and/or after hemodialysis. If neurotoxicity associated with cefepime therapy occurs, discontinue cefepime and institute appropriate supportive measures.

5.3 Clostridioides difficile

5.3 Clostridioides difficile -Associated Diarrhea Clostridioides difficile -associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Cefepime for Injection, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B, which contribute to the development of CDAD. Hypertoxin-producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use.

Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

5.4 Development of Drug-Resistant Bacteria

5.4 Development of Drug-Resistant Bacteria Prescribing cefepime for injection in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. As with other antimicrobials, prolonged use of cefepime for injection may result in overgrowth of nonsusceptible microorganisms.

Repeated evaluation of the patient's condition is essential. Should superinfection occur during therapy, appropriate measures should be taken.

5.5 Drug/Laboratory Test Interactions Urinary Glucose

5.5 Drug/Laboratory Test Interactions Urinary Glucose The administration of cefepime may result in a false-positive reaction for glucose in the urine when using some methods (e.g. Clinitest TM tablets) [see Drug Interactions (7.1)]. Coombs' Tests Positive direct Coombs' tests have been reported during treatment with cefepime for injection.

In patients who develop hemolytic anemia, discontinue the drug and institute appropriate therapy. Positive Coombs' test may be observed in newborns whose mothers have received cephalosporin antibacterial drugs before parturition. Prothrombin Time Many cephalosporins, including cefepime, have been associated with a fall in prothrombin activity.

Those at risk include patients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy. Prothrombin time should be monitored in patients at risk, and exogenous vitamin K administered as indicated.

Drug interactions

Drug or classSeverityEffectWhat to do
Aminoglycosides; potent loop diuretics (furosemide)Adjust or monitorNephrotoxicity reported with cephalosporins given with these drugs (label).Monitor kidney function.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed
Drug interactions (US label) US FDA label
  • Aminoglycosides: increased potential of nephrotoxicity and ototoxicity. Monitor renal function. (7.2)
  • Diuretics: nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide. Monitor renal function. (7.3)
7.1 Drug/Laboratory Test Interactions

7.1 Drug/Laboratory Test Interactions The administration of cefepime may result in a false-positive reaction for glucose in the urine with certain methods. It is recommended that glucose tests based on enzymatic glucose oxidase reactions be used.

7.2 Aminoglycosides

7.2 Aminoglycosides Monitor renal function if aminoglycosides are to be administered with cefepime for injection because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibacterial drugs.

7.3 Diuretics

7.3 Diuretics Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide. Monitor renal function when cefepime is concomitantly administered with potent diuretics.

Adverse reactions

Common

  • Local infusion reactions
  • Positive Coombs test
  • Low phosphorus; raised ALT, AST, PT and PTT
  • Rash

Serious

  • Neurotoxicity: encephalopathy, myoclonus, seizures, nonconvulsive status epilepticus (mainly unadjusted doses in kidney impairment)
  • Anaphylaxis (cross-reactivity with penicillins up to 10%)
  • Clostridioides difficile-associated diarrhea
renalcarematters.com, reviewed
Adverse reactions (US label) US FDA label
  • The following adverse reactions are discussed in the Warnings and Precautions section and below: Hypersensitivity Reactions [see Warnings and Precautions (5.1)] Neurotoxicity [see Warnings and Precautions (5.2)] Clostridioides difficile -Associated Diarrhea [see Warnings and Precautions (5.3)] The most common adverse reactions (incidence ≥ 1%) were local reactions, positive Coombs' test, decreased phosphorous, increased ALT and AST, increased PT and PTT and rash. (6.1)
  • At the highest dose (2 g every 8 hours), incidence of adverse reactions was ≥1% for rash, diarrhea, nausea, vomiting, pruritus, fever, and headache. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Sagent Pharmaceuticals at 1-866-625-1618 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In clinical trials using multiple doses of cefepime, 4137 patients were treated with the recommended dosages of cefepime (500 mg to 2 g intravenous every 12 hours).

There were no deaths or permanent disabilities thought related to drug toxicity. Sixty-four (1.5%) patients discontinued medication due to adverse reactions. Thirty-three (51%) of these 64 patients who discontinued therapy did so because of rash. The percentage of cefepime-treated patients who discontinued study drug because of drug-related adverse reactions was similar at daily doses of 500 mg, 1 g, and 2 g every 12 hours (0.8%, 1.1%, and 2%, respectively).

However, the incidence of discontinuation due to rash increased with the higher recommended doses. The following adverse reactions (Table 5) were identified in clinical trials conducted in North America (n=3125 cefepime-treated patients). Table 5: Adverse Reactions in Cefepime Multiple-Dose Dosing Regimens Clinical Trials in North America Incidence equal to or greater than 1% Local adverse reactions (3%), including phlebitis (1.3%), pain and/or inflammation (0.6%)*; rash (1.1%) Incidence less than 1% but greater than 0.1% Colitis (including pseudomembranous colitis), diarrhea, erythema, fever, headache, nausea, oral moniliasis, pruritus, urticaria, vaginitis, vomiting, anemia At the higher dose of 2 g every 8 hours, the incidence of adverse reactions was higher among the 795 patients who received this dose of cefepime.

They consisted of rash (4%), diarrhea (3%), nausea (2%), vomiting (1%), pruritus (1%), fever (1%), and headache (1%). The following (Table 6) adverse laboratory changes, with cefepime, were seen during clinical trials conducted in North America. Table 6: Adverse Laboratory Changes in Cefepime Multiple-Dose Dosing Regimens Clinical Trials in North America * Hypocalcemia was more common among elderly patients.

Clinical consequences from changes in either calcium or phosphorus were not reported. Incidence equal to or greater than 1% Positive Coombs' test (without hemolysis) (16.2%); decreased phosphorus (2.8%); increased Alanine Transaminase (ALT) (2.8%), Aspartate Transaminase (AST) (2.4%), eosinophils (1.7%); abnormal PTT (1.6%), Prothrombin Time (PT) (1.4%) Incidence less than 1% but greater than 0.1% Increased alkaline phosphatase, Blood Urea Nitrogen (BUN), calcium, creatinine, phosphorus, potassium, total bilirubin; decreased calcium*, hematocrit, neutrophils, platelets, White Blood Cells (WBC) A similar safety profile was seen in clinical trials of pediatric patients.

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of cefepime for injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

In addition to the adverse reactions reported during the North American clinical trials with cefepime, the following adverse reactions have been reported during worldwide postmarketing experience. Encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor, and coma), aphasia, myoclonus, seizures, and nonconvulsive status epilepticus have been reported [see Warnings and Precautions (5.2)].

Anaphylaxis including anaphylactic shock, transient leukopenia, neutropenia, agranulocytosis and thrombocytopenia, have been reported.

6.3 Cephalosporin-Class Adverse Reactions

6.3 Cephalosporin-Class Adverse Reactions In addition to the adverse reactions listed above that have been observed in patients treated with cefepime, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibacterial drugs: Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, renal dysfunction, toxic nephropathy, aplastic anemia, hemolytic anemia, hemorrhage, hepatic dysfunction including cholestasis, and pancytopenia.

Adverse reaction frequency tables (US label) US FDA label
Table 5: Adverse Reactions in Cefepime Multiple-Dose Dosing Regimens Clinical Trials in North America
Incidence equal to or greater than 1% Local adverse reactions (3%), including phlebitis (1.3%), pain and/or inflammation (0.6%)*; rash (1.1%)
Incidence less than 1% but greater than 0.1% Colitis (including pseudomembranous colitis), diarrhea, erythema, fever, headache, nausea, oral moniliasis, pruritus, urticaria, vaginitis, vomiting, anemia
Table 6: Adverse Laboratory Changes in Cefepime Multiple-Dose Dosing Regimens Clinical Trials in North America
* Hypocalcemia was more common among elderly patients. Clinical consequences from changes in either calcium or phosphorus were not reported.
Incidence equal to or greater than 1% Positive Coombs' test (without hemolysis) (16.2%); decreased phosphorus (2.8%); increased Alanine Transaminase (ALT) (2.8%), Aspartate Transaminase (AST) (2.4%), eosinophils (1.7%); abnormal PTT (1.6%), Prothrombin Time (PT) (1.4%)
Incidence less than 1% but greater than 0.1% Increased alkaline phosphatase, Blood Urea Nitrogen (BUN), calcium, creatinine, phosphorus, potassium, total bilirubin; decreased calcium*, hematocrit, neutrophils, platelets, White Blood Cells (WBC)

Monitoring parameters

  • CrCl for dose; neurotoxicity (encephalopathy, myoclonus, seizures, nonconvulsive status epilepticus), mainly with unadjusted doses in kidney impairment; stop cefepime if it occurs (label 5.2). Kidney function with aminoglycosides or loop diuretics. Kidney
  • CrCl for dose
  • Mental status and neurologic signs, especially in kidney impairment
  • Kidney function with aminoglycosides or loop diuretics
renalcarematters.com, reviewed

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary There are no cases of cefepime exposure during pregnancy reported from postmarketing experience or from clinical trials. Available data from published observational studies and case reports over several decades with cephalosporin use in pregnant women have not established drug-associated risks of major birth defects, miscarriage or adverse maternal or fetal outcomes (see Data).

Cefepime was not associated with adverse developmental outcomes in rats, mice, or rabbits when administered parenterally during organogenesis. The doses used in these studies were 1.6 (rats), approximately equal to (mice), and 0.3 times (rabbits) the recommended maximum human dose (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.

All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Human Data While available studies cannot definitively establish the absence of risk, published data from case-control studies and case reports over several decades have not identified an association with cephalosporin use during pregnancy and major birth defects, miscarriage, or other adverse maternal or fetal outcomes.

Available studies have methodologic limitations, including small sample size, retrospective data collection, and inconsistent comparator groups. Animal Data Cefepime was not embryocidal and did not cause fetal malformations when administered parenterally during the period of organogenesis to rats at doses up to 1000 mg/kg/day, to mice at doses up to 1200 mg/kg/day, or to rabbits at doses up to 100 mg/kg/day.

These doses are 1.6 times (rats), approximately equal to (mice), and 0.3 times (rabbits) the maximum recommended clinical dose based on body surface area.

Mechanism of action

12.1 Mechanism of Action Cefepime is a cephalosporin antibacterial drug [see Microbiology (12.4)].

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Similar to other beta-lactam antimicrobial agents, the time that the unbound plasma concentration of cefepime exceeds the MIC of the infecting organism has been shown to best correlate with efficacy in animal models of infection. However, the pharmacokinetic/pharmacodynamics relationship for cefepime has not been evaluated in patients.

Pharmacokinetics

Key PK parameters

BioavailabilityIM: completely absorbed
Half-lifeAbout 2 hours
Half-life in kidney failure (ESKD) kidney13.5 hours on hemodialysis; 19 hours on continuous peritoneal dialysis (label)
Volume of distributionAbout 18 L
Protein bindingAbout 20%
Renal excretion kidneyMainly renal; clearance falls in proportion to CrCl (label)
Dialyzability kidneyYes (about 68% per 3-hour hemodialysis)
renalcarematters.com, reviewed
Half-life and elimination (verbatim, US label)

Elimination of cefepime is principally via renal excretion with an average (±SD) half-life of 2 (±0.3) hours and total body clearance of 120 (±8) mL/min in healthy volunteers.

Metabolism and Excretion Cefepime is metabolized to N-methylpyrrolidine (NMP) which is rapidly converted to the N-oxide (NMP-N-oxide).

Urinary recovery of unchanged cefepime accounts for approximately 85% of the administered dose.

Because renal excretion is a significant pathway of elimination, patients with renal dysfunction and patients undergoing hemodialysis require dosage adjustment [see Dosage and Administration ( 2.3 )] .

The average half-life in patients requiring hemodialysis was 13.5 (±2.7) hours and in patients requiring continuous peritoneal dialysis was 19 (±2) hours.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Pharmacokinetic parameters for cefepime in healthy adult male volunteers (n=9) following single 30-minute infusions (IV) of cefepime 500 mg, 1 g, and 2 g are summarized in Table 7. Elimination of cefepime is principally via renal excretion with an average (±SD) half-life of 2 (±0.3) hours and total body clearance of 120 (±8) mL/min in healthy volunteers.

Cefepime pharmacokinetics are linear over the range 250 mg to 2 g. There is no evidence of accumulation in healthy adult male volunteers (n=7) receiving clinically relevant doses for a period of 9 days. Table 7: Mean Pharmacokinetic Parameters for Cefepime (±SD), Intravenous Administration Cefepime for Injection Parameter 500 mg IV 1 g IV 2 g IV C max, mcg/mL 39.1 (3.5) 81.7 (5.1) 163.9 (25.3) AUC, h•mcg/mL 70.8 (6.7) 148.5 (15.1) 284.8 (30.6) Number of subjects (male) 9 9 9 Pharmacokinetic parameters for cefepime following a single intramuscular injection are summarized in Table 8.

The pharmacokinetics of cefepime are linear over the range of 500 mg to 2 g intramuscularly and do not vary with respect to treatment duration. Table 8: Mean Pharmacokinetic Parameters for Cefepime (±SD), Intramuscular Administration Cefepime for Injection Parameter 500 mg IM 1 g IM 2 g IM C max, mcg/mL 13.9 (3.4) 29.6 (4.4) 57.5 (9.5) T max, h 1.4 (0.9) 1.6 (0.4) 1.5 (0.4) AUC, h•mcg/mL 60 (8) 137 (11) 262 (23) Number of subjects (male) 6 6 12 Absorption Following intramuscular (IM) administration, cefepime is completely absorbed.

Distribution The average steady-state volume of distribution of cefepime is 18 (±2) L. The serum protein binding of cefepime is approximately 20% and is independent of its concentration in serum. Concentrations of cefepime achieved in specific tissues and body fluids are listed in Table 9. Table 9: Mean Concentrations of Cefepime in Specific Body Fluids (mcg/mL) or Tissues (mcg/g) Tissue or Fluid Dose/ Route # of Patients Mean Time of Sample Post-Dose (h) Mean Concentration Blister Fluid 2 g IV 6 1.5 81.4 mcg/mL Bronchial Mucosa 2 g IV 20 4.8 24.1 mcg/g Sputum 2 g IV 5 4 7.4 mcg/mL Urine 500 mg IV 1 g IV 2 g IV 8 12 12 0 to 4 0 to 4 0 to 4 292 mcg/mL 926 mcg/mL 3120 mcg/mL Bile 2 g IV 26 9.4 17.8 mcg/mL Peritoneal Fluid 2 g IV 19 4.4 18.3 mcg/mL Appendix 2 g IV 31 5.7 5.2 mcg/g Gallbladder 2 g IV 38 8.9 11.9 mcg/g Prostate 2 g IV 5 1 31.5 mcg/g Data suggest that cefepime does cross the inflamed blood-brain barrier.

The clinical relevance of these data is uncertain at this time. Metabolism and Excretion Cefepime is metabolized to N-methylpyrrolidine (NMP) which is rapidly converted to the N-oxide (NMP-N-oxide). Urinary recovery of unchanged cefepime accounts for approximately 85% of the administered dose. Less than 1% of the administered dose is recovered from urine as NMP, 6.8% as NMP-N-oxide, and 2.5% as an epimer of cefepime.

Because renal excretion is a significant pathway of elimination, patients with renal dysfunction and patients undergoing hemodialysis require dosage adjustment [see Dosage and Administration (2.3)]. Specific Populations Patients with Renal impairment Cefepime pharmacokinetics have been investigated in patients with various degrees of renal impairment (n=30).

The average half-life in patients requiring hemodialysis was 13.5 (±2.7) hours and in patients requiring continuous peritoneal dialysis was 19 (±2) hours. Cefepime total body clearance decreased proportionally with creatinine clearance in patients with abnormal renal function, which serves as the basis for dosage adjustment recommendations in this group of patients [see Dosage and Administration (2.3)].

Patients with Hepatic impairment The pharmacokinetics of cefepime were unaltered in patients with hepatic impairment who received a single 1 g dose (n=11). Geriatric patients Cefepime pharmacokinetics have been investigated in elderly (65 years of age and older) men (n=12) and women (n=12) whose mean (SD) creatinine clearance was 74 (±15) mL/min.

There appeared to be a decrease in cefepime total body clearance as a function of creatinine clearance. Therefore, dosage administration of cefepime in the elderly should be adjusted as appropriate if the patient's creatinine clearance is 60 mL/min or less [see Dosage and Administration (2.3)]. Pediatric patients Cefepime pharmacokinetics have been evaluated in pediatric patients from 2 months to 11 years of age following single and multiple doses on every 8 hours (n=29) and every 12 hours (n=13) schedules.

Following a single intravenous dose, total body clearance and the steady-state volume of distribution averaged 3.3 (±1) mL/min/kg and 0.3 (±0.1) L/kg, respectively. The urinary recovery of unchanged cefepime was 60.4 (±30.4)% of the administered dose, and the average renal clearance was 2 (±1.1) mL/min/kg. There were no significant effects of age or gender (25 male vs. 17 female) on total body clearance or volume of distribution, corrected for body weight.

No accumulation was seen when cefepime was given at 50 mg per kg every 12 hours (n=13), while C max, AUC, and t ½ were increased about 15% at steady state after 50 mg per kg every 8 hours. The exposure to cefepime following a 50 mg per kg intravenous dose in a pediatric patient is comparable to that in an adult treated with a 2 g intravenous dose.

The absolute bioavailability of cefepime after an intramuscular dose of 50 mg per kg was 82.3 (±15)% in eight patients.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Cefepime 1 g Vial₱58.98–₱280.00Reference ₱84.38per vialDPRI procurement range
Cefepime 2 g Vial₱193.33–₱245.33Reference ₱193.33per vialDPRI procurement range
Cefepime 500 mg Vial₱65.34–₱144.00Reference ₱112.33per vialDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Cefepime (as hydrochloride)
PNF listingInj.: 500 mg, 1 g and 2 g vial (IM, IV)Restrictions: Reserve antimicrobial (PNF)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. cefepime · Sagent Pharmaceuticals [US FDA-approved label, version 24, August 3, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de477f37-40f6-4295-ae72-a2ee36a8922e
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
  5. Sagent Pharmaceuticals. (2026). Cefepime for injection, USP [Prescribing information; US FDA-approved label, ANDA065441, set ID de477f37-40f6-4295-ae72-a2ee36a8922e, version effective August 3, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de477f37-40f6-4295-ae72-a2ee36a8922e
  6. Li, L., Li, X., Xia, Y., Chu, Y., Zhong, H., Li, J., Liang, P., Bu, Y., Zhao, R., Liao, Y., Yang, P., Lu, X., & Jiang, S. (2020). Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy. Frontiers in Pharmacology, 11, Article 786. https://doi.org/10.3389/fphar.2020.00786
  7. Li, P. K.-T., Chow, K. M., Cho, Y., Fan, S., Figueiredo, A. E., Harris, T., Kanjanabuch, T., Kim, Y.-L., Madero, M., Malyszko, J., Mehrotra, R., Okpechi, I. G., Perl, J., Piraino, B., Runnegar, N., Teitelbaum, I., Wong, J. K.-W., Yu, X., & Johnson, D. W. (2022). ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Peritoneal Dialysis International, 42(2), 110–153. https://doi.org/10.1177/08968608221080586
  8. Tsai, Y. V., Soto, C., Crawford, G., & Dzintars, K. (2025). Important antimicrobial dosing considerations for transitions of care: Focus on thrice-weekly dosing in hemodialysis. American Journal of Health-System Pharmacy, 82(4), 203–210. https://doi.org/10.1093/ajhp/zxae259

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .